信达生物制药（Innovent Biologics）宣布与罗氏（Roche）达成全球独家合作与许可协议，以推进Delta样配体3（DLL3）靶向新一代抗体偶联药物（ADC）候选产品IBI3009的开发，旨在为晚期小细胞肺癌（SCLC）患者提供全新的治疗选择。IBI3009已在澳大利亚、中国和美国获得IND批准，并于2024年12月完成1期临床研究首例患者给药。

Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new ...

Chinese biotech Innovent Biologics (OTCPK:IVBIY) (OTCPK:IVBXF) has entered into a collaboration and licensing agreement with ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...

Innovent Biologics (IVBIY) secures second Chinese approval for lung cancer therapy Dovbleron developed with U.S. biotech ...

Innovent Biologics and Roche have entered a partnership and exclusive licence agreement to accelerate the development of a ...

在全球制药市场的激烈竞争中，Nuvation Bio的Taletrectinib刚刚在中国获得了首批药物批准。这不仅是一个科研成果的展示，更是对未来药物研发和临床应用的一个重要里程碑。让我们一起深入了解这个重大动态，看看它对行业和患者的影响。

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...

Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...

Innovent Biologics (HK:1801) has released an update.Don't Miss Our New Year's Offers:Discover the latest stocks recommended by top Wall Street ...